Intensity-modulated Radiation Therapy Combined with Concomitant Temozolomide for Brain Metastases from Lung Adenocarcinoma

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Sep 15

PMID 30214562

Citations 2

Authors

Jinli Li

Xiaoyan Chai

Ying Cao

Xiaochu Hu

Hongyu Zhu

Jianping Wang

Yiwei Wu

Affiliations

Soon will be listed here.

Abstract

Short-term efficacy, adverse effects and the impact on quality of life (QoL) of a concomitant treatment with intensity-modulated radiation therapy (IMRT) and temozolomide (TMZ) in patients with brain metastases (BMs) from lung adenocarcinoma were evaluated. This study sought to confirm the benefit of adding TMZ to IMRT in patients with BMs from lung adenocarcinoma. Nine patients were enrolled and received a dose of 30 Gy in 10 daily fractions to clinical tumor volume (CTV) according to IMRT, then additional dose of 9 Gy in 3 fractions of IMRT was delivered to gross tumor volume (GTV) only with concomitant TMZ (75 mg/m/day) orally during RT for 3 weeks. One patient achieved complete response (CR) (11.1%), 6 patients obtained partial response (PR) (66.7%), and there were no patients in progression. Therefore, objective response (OR) reached 77.8%. The main adverse effects included neutropenia, anemia, vomiting, fatigue and dizziness. Grade ≥3 of hematologic toxicities did not occur. However, the other 9 patients who received only intensity-modulated radiation had much worse results. The CR was 0, PR rate was 44.4%, OR rate was 44.4%. The results indicated that the benefit of adding TMZ to IMRT was confirmed in patients with BMs from lung adenocarcinoma. The treatment was active, a significant OR was observed, and achieved an improvement in QoL demonstrated by QoL grade (p<0.05).

Citing Articles

Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis.

Zhang C, Zhou W, Zhang D, Ma S, Wang X, Jia W Open Med (Wars). 2023; 18(1):20220574.

PMID: 36820064 PMC: 9938645. DOI: 10.1515/med-2022-0574.

Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review.

Belanger K, Ung T, Damek D, Lillehei K, Ormond D BMC Cancer. 2022; 22(1):367.

PMID: 35392834 PMC: 8988385. DOI: 10.1186/s12885-022-09340-7.

References

Tarnawski R, Michalecki L, Blamek S, Hawrylewicz L, Piotrowski T, Slosarek K . Feasibility of reducing the irradiation dose in regions of active neurogenesis for prophylactic cranial irradiation in patients with small-cell lung cancer. Neoplasma. 2011; 58(6):507-15. DOI: 10.4149/neo_2011_06_507. View

Kirby N, Chuang C, Pouliot J, Hwang A, Barani I . Physics strategies for sparing neural stem cells during whole-brain radiation treatments. Med Phys. 2011; 38(10):5338-44. DOI: 10.1118/1.3633946. View

Edwards A, Keggin E, Plowman P . The developing role for intensity-modulated radiation therapy (IMRT) in the non-surgical treatment of brain metastases. Br J Radiol. 2009; 83(986):133-6. PMC: 3473526. DOI: 10.1259/bjr/28596848. View

Tatar Z, Thivat E, Planchat E, Gimbergues P, Gadea E, Abrial C . Temozolomide and unusual indications: review of literature. Cancer Treat Rev. 2012; 39(2):125-35. DOI: 10.1016/j.ctrv.2012.06.002. View

Gamboa-Vignolle C, Ferrari-Carballo T, Arrieta O, Mohar A . Whole-brain irradiation with concomitant daily fixed-dose temozolomide for brain metastases treatment: a randomised phase II trial. Radiother Oncol. 2012; 102(2):187-91. DOI: 10.1016/j.radonc.2011.12.004. View

Wang Q, Jiang Z, Qi X, Lu S, Wang S, Leng C . Whole brain radiation therapy followed by intensity-modulated boosting treatment combined with concomitant temozolomide for brain metastases from non-small-cell lung cancer. Clin Transl Oncol. 2014; 16(11):1000-5. DOI: 10.1007/s12094-014-1190-x. View

Carbone D, Ding K, Roder H, Grigorieva J, Roder J, Tsao M . Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial. J Thorac Oncol. 2012; 7(11):1653-60. PMC: 3728561. DOI: 10.1097/JTO.0b013e31826c1155. View

Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P . Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol. 2002; 20(17):3644-50. DOI: 10.1200/JCO.2002.04.140. View

Wolff D, Abo-Madyan Y, Dobler B, Lohr F, Mai S, Polednik M . [Serial tomotherapy vs. MLC-IMRT (multileaf collimator intensity modulated radiotherapy) for simultaneous boost treatment large intracerebral lesions]. Z Med Phys. 2009; 19(1):58-66. DOI: 10.1016/j.zemedi.2008.07.003. View

10.

Mehta M, Paleologos N, Mikkelsen T, Robinson P, Ammirati M, Andrews D . The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2009; 96(1):71-83. PMC: 2808518. DOI: 10.1007/s11060-009-0062-7. View

11.

Cardama G, Gonzalez N, Maggio J, Menna P, Gomez D . Rho GTPases as therapeutic targets in cancer (Review). Int J Oncol. 2017; 51(4):1025-1034. PMC: 5592879. DOI: 10.3892/ijo.2017.4093. View

12.

Neuhaus T, Ko Y, Muller R, Grabenbauer G, Hedde J, Schueller H . A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer. 2009; 100(2):291-7. PMC: 2634726. DOI: 10.1038/sj.bjc.6604835. View

13.

Zhang J, Stevens M, Bradshaw T . Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol. 2011; 5(1):102-14. DOI: 10.2174/1874467211205010102. View

14.

Guerrieri M, Wong K, Ryan G, Millward M, Quong G, Ball D . A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer. 2004; 46(1):107-11. DOI: 10.1016/j.lungcan.2004.02.019. View

15.

Gaspar L, Mehta M, Patchell R, Burri S, Robinson P, Morris R . The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2009; 96(1):17-32. PMC: 2808517. DOI: 10.1007/s11060-009-0060-9. View

16.

Ferro M, Cilla S, Macchia G, Deodato F, Pierro A, Digesu C . On the cutting edge of intensity modulated radiotherapy and simultaneous integrated boost (IMRT-SIB): The case of a patient with 8 brain metastases. Rep Pract Oncol Radiother. 2015; 20(4):316-9. PMC: 4477119. DOI: 10.1016/j.rpor.2014.09.001. View

17.

. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990; 16(3):199-208. DOI: 10.1016/0168-8510(90)90421-9. View

18.

Gondi V, Pugh S, Tome W, Caine C, Corn B, Kanner A . Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014; 32(34):3810-6. PMC: 4239303. DOI: 10.1200/JCO.2014.57.2909. View

19.

Slade A, Stanic S . The impact of RTOG 0614 and RTOG 0933 trials in routine clinical practice: The US Survey of Utilization of Memantine and IMRT planning for hippocampus sparing in patients receiving whole brain radiotherapy for brain metastases. Contemp Clin Trials. 2016; 47:74-7. DOI: 10.1016/j.cct.2015.12.013. View

20.

Addeo R, De Rosa C, Faiola V, Leo L, Cennamo G, Montella L . Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer. 2008; 113(9):2524-31. DOI: 10.1002/cncr.23859. View